Fasenra 30mg Injection 1ml belongs to a class of drugs called interleukin inhibitors containing the active ingredient Benralizumab. Fasenra injection is used to treat severe eosinophilic asthma, a subtype of asthma caused by high levels of eosinophils in the blood and airways. It is also approved for treating eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease affecting blood vessels and organs.

Before using fasenra injection, it's essential to talk to your doctor if you have a history of allergic reactions to certain injections or medicines, have a parasitic infection, and live in an area where parasitic infections are common because this drug may weaken your ability to fight certain types of parasitic infections. If your asthma remains uncontrolled or worsens during treatment, immediately discuss this with your physician. This medicine is not intended to treat sudden asthma attacks. It should not be used as a rescue medication in such situations.

Do not use Fasenra 30mg Injection 1ml unless your doctor advises. Notify your physician if you are pregnant or planning to have a baby; think you may be pregnant so that your doctor may decide to give you this medicine if the expected benefits outweigh any potential risks. 

It is unknown whether Fasenra injection passes into breast milk and is safe to administer during breastfeeding. Inform your physician if you are a nursing mother. This medicine is not recommended for use in children under 18 because the safety and benefits of this medication have not been established in this age group. Parents and caregivers should consult physicians for appropriate asthma management and treatment options for children and adults.

The fasenra injection uses are:

• Treatment of severe eosinophilic asthma

Fasenra injection works by binding to a specific protein called interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils, a type of white blood cell that plays a key role in the inflammation and narrowing of the airways in asthma. By binding to IL-5Rα, this drug reduces the number of eosinophils in the blood and airways, helping to decrease airway inflammation and improve asthma symptoms.

It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Fasenra 30mg Injection 1ml, potentially affecting their effectiveness or causing side effects.

• Store Fasenra 30mg Injection 1ml in a refrigerator at (2°C-8°C).
• Do not freeze

Fasenra 30mg Injection 1ml will be given by injection under the skin (subcutaneous). Your doctor, nurse, or other healthcare professional will show you how to inject the medicine. Do not try to administer the medicine if you are well-trained. Your physician will decide the fasenra injection dosage based on your disease condition and severity. The Fasenra injection site is typically the thigh, abdomen, or the upper arm, depending on your healthcare provider’s instructions. Your physician will decide the Fasenra injection dosage based on your disease condition and severity.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. The fasenra injection side effects are as follows:

Serious side effects of fasenra injection are: 

• Hypersensitivity reactions

Common side effects of fasenra injection are:

• Headache
• Sore throat
• Rashes
• Fever
• Injection site reactions
• Muscle pain

Before taking Fasenra 30mg Injection 1ml, your doctor will likely assess your medical history and perform any necessary tests to determine if it is a suitable treatment for your specific condition. They will also provide you with instructions on how to take the medication properly and monitor your progress during treatment.

1. AstraZeneca, Electronic Medicines Compendium (EMC), [Revised on Dec 2022] [Accessed on 1st Sep 2023], https://www.medicines.org.uk/emc/files/pil.8918.pdf
2. AstraZeneca, [Revised on 20th Aug 2021] [Accessed on 1st Sep 2023], https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/fasenra-product%20monograph-en.pdf
3. Corrado Pelaia et al., Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma, BioMed Research International, 2018, [Accessed on 1st Sep 2023], https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971345/pdf/BMRI2018-4839230.pdf